Katy Perry has appealed a Federal Court decision handed down on 21 April 2023 by Markovic J in Australia (Taylor v Killer Queen, LLC (No 5) [2023] FCA 364) that found her...
I’ll cry about it later – Katy Perry appeals AU trade mark loss
read more
No issue estoppel in Australian Patent Office proceedings
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
Use of a Trade Mark in Patent Claims not limited to the Trade Marked Goods so no Lack of Clarity
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
BioBlast w/e 2 Jun 23
01 JUN 2023 | EU | New indication alert: EC approves Novartis’ Cosentyx® (secukinumab) for HS Novartis announced that the European Commission (EC) has approved its Cosentyx®...
Schlam dunk – Federal Court makes Norwich Pharmacal orders against third party new employer
Jackson J in Austin Engineering Pty Ltd v Podulova & Ors [2023] FCA 419 issued interlocutory Norwich Pharmacal orders against ex-employee Anastasis Podulova and her new...
Pearce IP joins GBMA: Working with GBMA to enable access to affordable medicines
Pearce IP, an award-winning Australian boutique Intellectual Property firm, specialising in the pharma, biopharma and life sciences industries, has joined Australia’s peak body...
BioBlast w/e 26 May 23
26 MAY 2023 | EU | Celltrion files MAA with EMA for biosimilar to Janssen’s Stelara® (ustekinumab) Korea Biomed has reported that Celltrion filed a marketing authorisation...
PiPCast™ | Best Method and why it is relevant to patents in Australia
PiPCast™ | Best Method and why it is relevant to patents in Australia
Beware the shifting sands of patent term extensions (PTE) in Australia
Recent Australian decisions have resulted in both new opportunities to challenge patent term extensions in Australia and new patent prosecution practices to shield against them....
PiPCast™ | Patent oppositions & litigation – what about estoppel?
PiPCast™ | Patent oppositions & litigation – what about estoppel?
BioBlast w/e 22 May 23
22 MAY 2023 | US | Janssen and Amgen settle Stelara® (ustekinemab) biosimilar patent dispute The US District Court of Delaware has dismissed with prejudice. The parties agreed...
Pearce IP leaders recognised as 2023 MIP Patent Stars
Pearce IP congratulates two of its leaders, Founder and CEO Naomi Pearce, and Special Counsel Jacinta Flattery-O’Brien PhD, who were honoured this week as MIP Patent stars for...
Grains of Justice | Preliminary discovery order extended to wheat product samples in CSIRO case
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
BioBlast w/e 12 May 23
11 MAY 2023| EU | Celltrion to supply Vegzelma® (bevacizumab) in Italy and Belgium Korea Biomed has reported that Celltrion Healthcare has won bids to supply Vegzelma®,...
BioBlast w/e 05 May 23
04 MAY 2023 | CN | Boan Biotech commences phase III clinical trials for Prolia®/Xgeva® (denosumab) biosimilar Luye Pharma announced that it has enrolled its first subject in an...
Poor Drafting and Poor Choice of Expert Brings Calix Process Patent To Boiling Point
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
BioBlast w/e 28 Apr 23
28 April 2023 | US | FDA advisory committee supports approval of Merck’s Lynparza® (olaparib) combination for first line treatment of prostate cancer Merck announced that the...
Marlow Foods edible fungi patent amended but still obvious
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
BioBlast w/e 21 Apr 23
20 April 2023 | CA | New indication alert: Health Canada issues notice of compliance for Regeneron/Sanofi’s Dupixent® (dupilumab) in children > 6 months Sanofi and Regeneron...
BioBlast f/e 14 Apr 23
Significant biosimilar activities this fortnight include: 13 April 2023 | US | Alvotech CRL provided to FDA regarding high concentration buffer free biosimilar adalimumab 12...
Webinar | Pharmaceutical Patent Term Extensions The Good, The Bad and the Ugly
Webinar | Pharmaceutical Patent Term Extensions The Good, The Bad and the Ugly
BioBlast w/e 31 Mar 23: Humira® AU price reduction | EMA recommends Samsung’s EPYSQLI™ eculizumab | US Supreme Court hears Amgen v Sanofi | Eli Lilly $1B mAb manufacture investment in Ireland | Daiichi Enhertu® JP approval | Coya and Dr. Reddy’s ww development agreement … and more!
Significant biosimilar activities this week include: 01 April 2023 | AU | Humira® 24.39% PBS price drop 30 March 2023 | EU | EMA CHMP gives nod to Samsung Bioepis’ Epysqli™...
High Court finds no wrinkles in PROTOX and INHIBOX brands
The High Court recently issued its decision in the case of Self Care IP Holdings Pty Ltd & Anor v Allergan Australia Pty Ltd & Anor [2023] HCA 8. The court surprised many...
BioBlast w/e 24 Mar 23: IPRs re Regeneron aflibercept patents | NMPA approves Xgeva® (denosumab) | FDA approves Hyrimoz® (adalimumab) | and more…
Significant biosimilar activities this week include: 22 March 2023 | US | PTAB institutes Celltrion and Samsung IPRs re Regeneron’s key aflibercept patents 21 March 2023 | CN |...
Recent BioBlast® Updates
Get our Pearce IP Blogs & BioBlast® sent directly to your inbox
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.